Alterity Therapeutics (NASDAQ:ATHE) Stock Price Expected to Rise, Maxim Group Analyst Says

Alterity Therapeutics (NASDAQ:ATHE) had its price target boosted by research analysts at Maxim Group from $8.00 to $12.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 150.00% from the company’s current price.

Alterity Therapeutics Stock Performance

Shares of ATHE stock opened at $4.80 on Thursday. The firm has a 50 day moving average price of $2.78 and a two-hundred day moving average price of $1.83. Alterity Therapeutics has a 12-month low of $1.00 and a 12-month high of $5.87.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its holdings in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.